More Than Just Humira: US Biosimilars Enjoy An Eventful 2023

Adalimumab Competition Hits, Firms Settle On Stelara And New First Biosimilars Approved

31 Dec 2023

The launch of competition to Humira was the main event for US biosimilars this year – but a number of other key developments also took place in 2023, including settlements on Stelara that set up a series of launches in 2025, as well as first approvals for ustekinumab, natalizumab and tocilizumab biosimilars.

2023 date with arrow on metal dial — Several Humira biosimilars launched simultaneously in 2023

In 2023, one story dominated the headlines for the US biosimilars sector: the debut of biosimilar competition to AbbVie’s top-selling Humira (adalimumab) immunology brand.

A series of patent settlements between biosimilar sponsors and the originator had paved the way for multiple launches throughout this...